BioSpace News Archive

SAN JOSE, Calif. and DARMSTADT, Germany, April 02, 2020 (GLOBE NEWSWIRE) -- Align Technology, Inc. (Align) (Nasdaq: ALGN) today announced that it has completed the acquisition of privately-held exocad Global Holdings GmbH (exocad), a global leader in the dental CAD/CAM software market that offers fully integrated workflows to dental labs and dental practices via a broad customer base of partners and resellers in over 150 countries. The acquisition of exocad broadens Align’s digital platform

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins today provided an update on the impact of the COVID-19 pandemic on the Company and its clinical trial activities. As the global COVID-19 pandemic continues to quickly evolve, we have put measures in place intended to safeguard the health of our employees in line with many other companies. In doing so, we aim to do our part to help s

Newly created role will oversee the translation of programs from research stage into the clinic

Rgenta Therapeutics, a new biotechnology company focusing on developing RNA-targeting medicines for historically undruggable disease-relevant targets, announced today that it closed a $20 Million seed investment, co-led by Boehringer Ingelheim Venture Fund and Matrix Partners China. Rounding out the series seed syndicate are two

Nevro Corp. announced the pricing of concurrent underwritten public offerings of 1,625,000 shares of its common stock at a public offering price of $84.00 per share for gross proceeds, before deducting underwriting discounts and commissions and estimated offering costs, of approximately $136,500,000 and $165,000,000 aggregate amount of its 2.75% convertible senior notes due 2025.

Proceeds include a unilateral option for the investment of 6 million ILS by the company’s controlling shareholders and additional investors, including company Chair, Jonathan Kolber, Dr. Dadi Segal, CEO, and Ran Nussbaum.

IVERIC bio, Inc. reported that on April 1, 2020, the Company granted newly hired employees equity-based awards.

Fluidigm Corporation announced that Fluidigm® CyTOF® technology was used in a clinical study producing preliminary evidence that mesenchymal stem cell therapy improves outcomes in patients with COVID-19 pneumonia, providing key information about potential mechanisms of action of the treatment strategy.

Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company, is pleased to announce that the protocol for a planned physician initiated phase 2 clinical study of NP-120 for COVID-19 infected patients in South Korea has been finalized.

Aesthetic Medical International Holdings Group Limited announced the Company, through its affiliates, entered into definitive agreements to acquire controlling interest in two treatment centers in March 2020.